How I treat von Willebrand disorders in older adults

2.

Rodeghiero

F

,

Castaman

G

,

Dini

E

.

Epidemiological investigation of the prevalence of von Willebrand's disease

.

Blood

.

1987

;

69

(

2

):

454

-

459

.

3.

Michael Soucie

J

,

Miller

CH

,

Byams

VR

, et al.

Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States

.

Haemophilia

.

2021

;

27

(

3

):

445

-

453

.

4.

Federici

AB

,

Budde

U

,

Rand

JH

.

Acquired von Willebrand syndrome 2004: International Registry--diagnosis and management from online to bedside

.

Hamostaseologie

.

2004

;

24

(

1

):

50

-

55

.

5.

Balleisen

L

,

Bailey

J

,

Epping

PH

,

Schulte

H

,

van de Loo

J

.

Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause

.

Thromb Haemost

.

1985

;

54

(

2

):

475

-

479

.

6.

Favaloro

EJ

,

Franchini

M

,

Lippi

G

.

Aging hemostasis: changes to laboratory markers of hemostasis as we age - a narrative review

.

Semin Thromb Hemost

.

2014

;

40

(

6

):

621

-

633

.

7.

Favaloro

EJ

,

Soltani

S

,

McDonald

J

,

Grezchnik

E

,

Easton

L

.

Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors

.

Blood Coagul Fibrinolysis

.

2005

;

16

(

8

):

597

-

605

.

8.

Ariëns

RA

,

Kohler

HP

,

Mansfield

MW

,

Grant

PJ

.

Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension

.

Arterioscler Thromb Vasc Biol

.

1999

;

19

(

8

):

2012

-

2016

.

9.

Alavi

P

,

Rathod

AM

,

Jahroudi

N

.

Age-associated increase in thrombogenicity and its correlation with von Willebrand factor

.

J Clin Med

.

2021

;

10

(

18

):

4190

.

10.

Albánez

S

,

Ogiwara

K

,

Michels

A

, et al.

Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms

.

J Thromb Haemost

.

2016

;

14

(

5

):

953

-

963

.

11.

Kalot

MA

,

Husainat

N

,

El Alayli

A

, et al.

von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis

.

Blood Adv

.

2022

;

6

(

1

):

62

-

71

.

12.

Miletich

J

,

Sherman

L

,

Broze

G

.

Absence of thrombosis in subjects with heterozygous protein C deficiency

.

N Engl J Med

.

1987

;

317

(

16

):

991

-

996

.

13.

Boerger

LM

,

Morris

PC

,

Thurnau

GR

,

Esmon

CT

,

Comp

PC

.

Oral contraceptives and gender affect protein S status

.

Blood

.

1987

;

69

(

2

):

692

-

694

.

14.

MacCallum

PK

,

Cooper

JA

,

Martin

J

,

Howarth

DJ

,

Meade

TW

,

Miller

GJ

.

Associations of protein C and protein S with serum lipid concentrations

.

Br J Haematol

.

1998

;

102

(

2

):

609

-

615

.

15.

Yamamoto

K

,

Takeshita

K

,

Kojima

T

,

Takamatsu

J

,

Saito

H

.

Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly

.

Cardiovasc Res

.

2005

;

66

(

2

):

276

-

285

.

16.

Lippi

G

,

Favaloro

EJ

,

Cervellin

G

.

A review of the value of D-dimer testing for prediction of recurrent venous thromboembolism with increasing age

.

Semin Thromb Hemost

.

2014

;

40

(

6

):

634

-

639

.

17.

Segal

JB

,

Moliterno

AR

.

Platelet counts differ by sex, ethnicity, and age in the United States

.

Ann Epidemiol

.

2006

;

16

(

2

):

123

-

130

.

18.

Le Blanc

J

,

Lordkipanidzé

M

.

Platelet function in aging

.

Front Cardiovasc Med

.

2019

;

6

:

109

.

19.

Rydz

N

,

Grabell

J

,

Lillicrap

D

,

James

PD

.

Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease

.

Haemophilia

.

2015

;

21

(

5

):

636

-

641

.

20.

Borghi

M

,

Guglielmini

G

,

Mezzasoma

AM

, et al.

Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?

.

Haematologica

.

2017

;

102

(

11

):

e431

-

e433

.

21.

Sanders

YV

,

Giezenaar

MA

,

Laros-van Gorkom

BA

, et al.

von Willebrand disease and aging: an evolving phenotype

.

J Thromb Haemost

.

2014

;

12

(

7

):

1066

-

1075

.

22.

Tosetto

A

,

Rodeghiero

F

,

Castaman

G

, et al.

A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)

.

J Thromb Haemost

.

2006

;

4

(

4

):

766

-

773

.

23.

Atiq

F

,

Meijer

K

,

Eikenboom

J

, et al.

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease

.

Br J Haematol

.

2018

;

182

(

1

):

93

-

105

.

24.

Flood

VH

,

Christopherson

PA

,

Gill

JC

, et al.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States

.

Blood

.

2016

;

127

(

20

):

2481

-

2488

.

25.

O'Brien

JR

,

Green

PJ

,

Salmon

G

, et al.

Desmopressin and myocardial infarction

.

Lancet

.

1989

;

333

(

8639

):

664

-

665

.

26.

Lowe

GD

.

Desmopressin and myocardial infarction

.

Lancet

.

1989

;

1

(

8643

):

895

-

896

.

27.

Bond

L

,

Bevan

D

.

Myocardial infarction in a patient with hemophilia treated with DDAVP

.

N Engl J Med

.

1988

;

318

(

2

):

121

.

28.

Feldman

EA

,

Meola

G

,

Zyck

S

, et al.

Retrospective assessment of desmopressin effectiveness and safety in patients with antiplatelet-associated intracranial hemorrhage

.

Crit Care Med

.

2019

;

47

(

12

):

1759

-

1765

.

29.

Gunther

M

,

Witenko

CJ

,

Prust

M

,

Salerno

D

,

Berger

K

.

The safety and efficacy of desmopressin in patients with intracranial hemorrhage and a history of alcohol use

.

J Intensive Care Med

.

2022

;

37

(

6

):

825

-

832

.

30.

Gayet-Ageron

A

,

Prieto-Merino

D

,

Ker

K

,

Shakur

H

,

Ageron

FX

,

Roberts

I

, et al.

Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients

.

Lancet

.

2018

;

391

(

10116

):

125

-

132

.

31.

Nikolaou

VS

,

Masouros

P

,

Floros

T

,

Chronopoulos

E

,

Skertsou

M

,

Babis

GC

.

Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial

.

Bone Joint J

.

2021

;

103-b

(

3

):

442

-

448

.

32.

Porter

SB

,

Spaulding

AC

,

Duncan

CM

,

Wilke

BK

,

Pagnano

MW

,

Abdel

MP

.

Tranexamic acid was not associated with increased complications in high-risk patients with hip fracture undergoing arthroplasty

.

J Bone Joint Surg Am

.

2021

;

103

(

20

):

1880

-

1889

.

33.

Poeran

J

,

Chan

JJ

,

Zubizarreta

N

,

Mazumdar

M

,

Galatz

LM

,

Moucha

CS

.

Safety of tranexamic acid in hip and knee arthroplasty in high-risk patients

.

Anesthesiology

.

2021

;

135

(

1

):

57

-

68

.

34.

Myles

PS

,

Smith

JA

,

Forbes

A

, et al.

Tranexamic acid in patients undergoing coronary-artery surgery

.

N Engl J Med

.

2017

;

376

(

2

):

136

-

148

.

35.

Chornenki

NLJ

,

Um

KJ

,

Mendoza

PA

, et al.

Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: a systematic review and meta-analysis

.

Thromb Res

.

2019

;

179

:

81

-

86

.

36.

Gernsheimer

TB

,

Brown

SP

,

Triulzi

DJ

, et al.

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial

.

Blood

.

2022

;

140

(

11

):

1254

-

1262

.

37.

Connell

NT

,

Flood

VH

,

Brignardello-Petersen

R

, et al.

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

.

Blood Adv

.

2021

;

5

(

1

):

301

-

325

.

38.

Alphanate

.

Properties of treatment options for von Willebrand disease (VWD)

. Accessed 2 October 2023. https://www.alphanate.com/documents/729928/730168/Alphanate+Product+Properties+Chart+Patient.pdf/490e3dcd-c54b-4a08-80ac-b00cf69ddc7d?t=15145388630002017.

39.

Alphanate

.

Prescribing information. Grifols

. Accessed 2 October 2023. https://www.alphanate.com/documents/729928/730168/Alphanate+PI_3057619_8.5x11_22668_Secured.pdf/3e2c7c1d-62f7-66c4-e98b-f00391adf708?t=16399954777782021.

40.

CSL Behring

.

Dosing overview

. Accessed 2 October 2023. https://www.humate-p.com/hcp/about-humate-p/dosing#:∼:text=VWF%3ARCo%20and%20FVIII%20content,raising%20FVIII%20to%20supernormal%20levels.

41.

Humate-P

. Prescribing information.

CSL Behring

;

2020

Accessed 2 October 2023. https://labeling.cslbehring.com/pi/us/humate-p/en/humate-p-prescribing-information.pdf.

42.

Wilate

. Prescribing information.

Octapharma

;

2020

Accessed 2 October 2023. https://wilateusa.com/hcp/wp-content/uploads/sites/2/2021/11/wilate-full-prescribing-information.pdf.

43.

Baxalta

.

Prescribing information

. Accessed 2 October 2023. https://www.fda.gov/media/94863/download.

44.

James

PD

,

Connell

NT

,

Ameer

B

, et al.

ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease

.

Blood Adv

.

2021

;

5

(

1

):

280

-

300

.

45.

Huang

JN

,

Koerper

MA

.

Factor V deficiency: a concise review

.

Haemophilia

.

2008

;

14

(

6

):

1164

-

1169

.

46.

Choufani

EB

,

Sanchorawala

V

,

Ernst

T

, et al.

Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy

.

Blood

.

2001

;

97

(

6

):

1885

-

1887

.

47.

Chuliber

FA

,

Schutz

NP

,

Viñuales

ES

, et al.

Nonimmune-acquired factor XIII deficiency: a cause of high volume and delayed postoperative hemorrhage

.

Blood Coagul Fibrinolysis

.

2020

;

31

(

8

):

511

-

516

.

48.

Biswas

A

,

Ivaskevicius

V

,

Thomas

A

,

Oldenburg

J

.

Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms

.

Hamostaseologie

.

2014

;

34

(

2

):

160

-

166

.

49.

Ichinose

A

;

Japanese Collaborative Research Group on AH13

.

Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: a summary of 93 patients

.

Blood Rev

.

2017

;

31

(

1

):

37

-

45

.

50.

Dear

A

,

Brennan

SO

,

Sheat

MJ

,

Faed

JM

,

George

PM

.

Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain

.

Haematologica

.

2007

;

92

(

11

):

e111

-

e117

.

51.

Gralnick

HR

,

Henderson

E

.

Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment

.

Cancer

.

1971

;

27

(

6

):

1313

-

1320

.

52.

Mumford

AD

,

O'Donnell

J

,

Gillmore

JD

,

Manning

RA

,

Hawkins

PN

,

Laffan

M

.

Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis

.

Br J Haematol

.

2000

;

110

(

2

):

454

-

460

.

53.

Federici

AB

,

Rand

JH

,

Bucciarelli

P

, et al.

Acquired von Willebrand syndrome: data from an international registry

.

Thromb Haemost

.

2000

;

84

(

2

):

345

-

349

.

54.

Horiuchi

H

,

Doman

T

,

Kokame

K

,

Saiki

Y

,

Matsumoto

M

.

Acquired von Willebrand syndrome associated with cardiovascular diseases

.

J Atheroscler Thromb

.

2019

;

26

(

4

):

303

-

314

.

55.

Warkentin

TE

,

Moore

JC

,

Anand

SS

,

Lonn

EM

,

Morgan

DG

.

Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome

.

Transfus Med Rev

.

2003

;

17

(

4

):

272

-

286

.

56.

Federici

AB

,

Stabile

F

,

Castaman

G

,

Canciani

MT

,

Mannucci

PM

.

Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches

.

Blood

.

1998

;

92

(

8

):

2707

-

2711

.

57.

Lavin

M

,

Ryan

K

,

White

B

,

Byrne

M

,

O'Connell

NM

,

O'Donnell

JS

.

A role for intravenous immunoglobulin in the treatment of acquired von Willebrand syndrome associated with IgM gammopathy

.

Haemophilia

.

2018

;

24

(

1

):

e22

-

e25

.

58.

Engelen

ET

,

van Galen

KP

,

Schutgens

RE

.

Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature

.

Haemophilia

.

2015

;

21

(

4

):

419

-

429

.

59.

Green

A

,

Shen

YMP

,

Nelson

AT

, et al.

Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy

.

Ann Hematol

.

2022

;

101

(

12

):

2627

-

2631

.

60.

Mazoyer

E

,

Fain

O

,

Dhote

R

,

Laurian

Y

.

Is rituximab effective in acquired von Willebrand syndrome?

.

Br J Haematol

.

2009

;

144

(

6

):

967

-

968

.

61.

Hawken

J

,

Knott

A

,

Alsakkaf

W

,

Clark

A

,

Fayyaz

F

.

Rituximab to the rescue: novel therapy for chronic gastrointestinal bleeding due to angiodysplasia and acquired von Willebrand syndrome

.

Frontline Gastroenterol

.

2019

;

10

(

4

):

434

-

437

.

62.

Ammann

EM

,

Haskins

CB

,

Fillman

KM

, et al.

Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs

.

Am J Hematol

.

2016

;

91

(

6

):

594

-

605

.

63.

Daniel

GW

,

Menis

M

,

Sridhar

G

, et al.

Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010

.

Transfusion

.

2012

;

52

(

10

):

2113

-

2121

.

64.

Kapoor

M

,

Hunt

I

,

Spillane

J

, et al.

IVIg-exposure and thromboembolic event risk: findings from the UK Biobank

.

J Neurol Neurosurg Psychiatry

.

2022

;

93

(

8

):

876

-

885

.

65.

Guo

Y

,

Tian

X

,

Wang

X

,

Xiao

Z

.

Adverse effects of immunoglobulin therapy

.

Front Immunol

.

2018

;

9

:

1299

.

66.

Drelich

DA

,

Bray

PF

,

Herman

JH

.

Immunoglobulin therapy and thrombosis: coincidence or causation?

.

Transfusion

.

2012

;

52

(

10

):

2075

-

2077

.

67.

Meijers

JC

,

Tekelenburg

WL

,

Bouma

BN

,

Bertina

RM

,

Rosendaal

FR

.

High levels of coagulation factor XI as a risk factor for venous thrombosis

.

N Engl J Med

.

2000

;

342

(

10

):

696

-

701

.

68.

Cheng

MJ

,

Christmas

C

.

Special considerations with the use of intravenous immunoglobulin in older persons

.

Drugs Aging

.

2011

;

28

(

9

):

729

-

736

.

69.

Seaman

CD

,

Yabes

J

,

Comer

DM

,

Ragni

MV

.

Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register

.

J Thromb Haemost

.

2015

;

13

(

11

):

1999

-

2003

.

70.

Hassan

SA

,

Amer

S

,

Qureshi

W

,

Alirhayim

Z

,

Kuriakose

P

.

Treating symptomatic coronary artery disease in patients with von Willebrand disease

.

Hematol Oncol Stem Cell Ther

.

2013

;

6

(

3-4

):

101

-

104

.